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Necrotizing enterocolitis (NEC) is the most devastating gastrointestinal disease of prema-
turity. Although the precise cause is not well understood, the main risk factors thought 
to contribute to NEC include prematurity, formula feeding, and bacterial colonization. 
Recent evidence suggests that NEC develops as a consequence of intestinal hyper- 
responsiveness to microbial ligands upon bacterial colonization in the preterm infant, 
initiating a cascade of aberrant signaling events, and a robust pro-inflammatory mucosal 
immune response. We now have a greater understanding of important mechanisms of 
disease pathogenesis, such as the role of cytokines, immunoglobulins, and immune 
cells in NEC. In this review, we will provide an overview of the mucosal immunity of 
the intestine and the relationship between components of the mucosal immune system 
involved in the pathogenesis of NEC, while highlighting recent advances in the field that 
have promise as potential therapeutic targets. First, we will describe the cellular compo-
nents of the intestinal epithelium and mucosal immune system and their relationship to 
NEC. We will then discuss the relationship between the gut microbiota and cell signaling 
that underpins disease pathogenesis. We will conclude our discussion by highlighting 
notable therapeutic advancements in NEC that target the intestinal mucosal immunity.
Keywords: necrotizing enterocolitis, innate immunity, mucosa, intestine, toll-like receptor 4, human milk 
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iNTRODUCTiON
Necrotizing enterocolitis (NEC) is notably the most lethal gastrointestinal disease of premature 
infants. The disease prevalence is approximately 7% of infants born between 500 and 1,500 g in the 
United States and Canada (1–3). Unfortunately, both the treatment approach and mortality have 
remained unchanged for decades with a mortality rate as high as 42% (4). At the same time, NEC rep-
resents a significant economic burden on the health system with an estimated annual cost upwards of 
one billion dollars in the United States (2, 5–7). These challenges fuel the need to understand disease 
pathogenesis so as to develop novel therapeutic and preventative strategies. Presently, it is believed 
that the immature intestine of premature infants exists in a hyper-active state due to abnormal 
bacterial colonization, which ultimately results in a robust inflammatory response and impairment 
of intestinal perfusion, thereby predisposing infants to NEC (2, 7, 8). Current research suggests the 
intestinal immune system is intricately involved in this process, which is comprised of the intestinal 
epithelium, immune cells, and commensal bacteria that maintain gastrointestinal homeostasis. Here, 
we will review the current knowledge of intestinal mucosal immunity in relation to NEC. First, we 
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will discuss the cell types that comprise the intestinal immune 
system with attention to how these cells are involved in NEC. 
We will then describe the role of the innate immune system with 
specific attention to toll-like receptor 4 (TLR4) signaling in the 
pathogenesis of NEC. We will then review the role of gut micro-
biota in our current understanding of this disease. Finally, we will 
describe advancements in potential treatment strategies rooted in 
our current understanding of the relationship between mucosal 
immunity and the development of NEC.
CeLLS OF THe iNTeSTiNAL  
iMMUNe SYSTeM
In order to understand the pathogenesis of NEC, it is important 
to appreciate the role of the immune system in the maintenance of 
gastrointestinal homeostasis. We will first describe the role of epi-
thelium and immune cells in mucosal immunity and then describe 
their role in the development of NEC with specific attention to the 
interplay of these cell types and the signaling pathways involved.
The intestinal epithelium
The epithelium represents the first layer of defense, comprised 
of at least seven differentiated cell types that together maintain 
barrier integrity and provide defense against pathogens with the 
presence of tight junctions (9). The epithelium has two distinct 
structures: the villus and the crypt. The villus contains entero-
cytes, goblet cells, enteroendocrine cells, and tuft cells, whereas 
the crypt houses transit amplifying cells, Paneth cells, and stem 
cells (Figure 1) (10). Stem cells expressing leucine-rich containing 
G protein-coupled receptor 5 (Lgr5) are capable of generating all 
cell types of the epithelium (11, 12). Together, these cells comprise 
the epithelium, which we will now discuss in further detail.
enterocytes
Enterocytes (IECs) are the predominant absorptive cells of the 
epithelium defined by the presence of microvilli, but the role of 
enterocytes is not limited to nutrient absorption; rather, they are 
important cells in the preservation of intestinal integrity and 
mucosal immunity (13–16). IECs, as the most numerous cells of 
the epithelium, provide the physical barrier between the lumen 
of the gastrointestinal tract and the lamina propria via the main-
tenance of tight junctions (14). They originate from within the 
intestinal crypts and migrate along the villi, at which point they 
undergo apoptosis, renewing the epithelium every 3–5 days in a 
continuous cycle of IEC proliferation, migration, and apoptosis 
in mouse studies (17). This cycle is crucial for intestinal homeo-
stasis; however, aberrancy in this process can lead to disastrous 
effects, such as bacterial translocation, which we will discuss in 
the context of NEC in a later section (18). IECs are notable for the 
presence of several pattern-recognition receptors (PRRs), such as 
toll-like receptors (TLRs) and nucleotide-binding oligomerization 
domains (NODs), thereby aiding in the clearance of pathogenic 
bacteria while maintaining a population of commensal bacteria 
(15, 16, 19, 20). We will describe TLRs and NODs more exten-
sively in a later section with specific attention to the relationship 
between TLR4 expression by enterocytes and gut barrier integ-
rity. Moreover, IECs also express major histocompatibility class 
(MHC) I and II molecules and non-classical MHC molecules, 
allowing IECs to process and present antigens to the immune 
cells of the intestine (21, 22). In doing so, there is a direct com-
munication between the antigens within the lumen and the cells 
of the lamina propria (Figure  1). Accordingly, enterocytes are 
vital cells of the epithelium with the roles in the maintenance of 
the gut barrier and commensal bacteria, absorption of nutrients, 
and communication with the immune cells of the lamina propria.
Goblet Cells
Goblet cells are particularly important with their role in generat-
ing the mucus layer of the intestine, preventing the interaction 
between pathogenic bacteria and the epithelium, while provid-
ing support for commensal bacteria, antimicrobial peptides 
(AMPs), and secretory immunoglobulin A (IgA) (23). Moreover, 
goblet cells are also capable of delivering luminal antigens to 
a subset of underlying dendritic cells (DCs), CD103+ lamina 
propria DCs, which have tolerogenic properties, thereby assist-
ing with the maintenance of commensal bacteria and intestinal 
homeostasis (24).
Goblet cell differentiation is determined by the activity of 
the Notch signaling pathway (25). Sodhi et al. (26) determined 
that the innate immune receptor TLR4 regulates Notch signaling 
and subsequent goblet cell development in the small intestine, 
such that TLR4 signaling prevented goblet cell differentiation 
independent from the influence of the microbiota. Furthermore, 
Notch signaling was found to be increased in mice as well as 
premature infants with NEC, whereas inhibition of the Notch 
pathway led to an increased number of goblet cells and attenu-
ated experimental NEC in mice (26). This study highlights the 
regulation by TLR4 and Notch signaling in NEC pathogenesis.
Goblet cells secrete glycoproteins called mucins, of which, the 
Muc2 mucin is of critical importance in maintaining an inner 
mucus layer impervious to pathogenic bacteria, while simultane-
ously creating an outer mucus layer and providing an ideal habitat 
for commensal bacteria (27). Notably, ileal Muc2 is decreased in 
NEC and depletion of intestinal goblet cells increases susceptibil-
ity and severity of experimental NEC (28, 29). This subsequent 
decrease in mechanical defenses increases the vulnerability of the 
epithelium to pathogenic bacteria (26, 30), which can be further 
exacerbated by decreased intestinal motility in the setting of 
prematurity (31, 32). Abnormal goblet cell function is implicated 
in the development of NEC and mechanisms to enhance goblet 
cell production and/or function may provide a unique way to 
prevent the disease.
Paneth Cells
Paneth cells also provide a unique source of protection in the 
maintenance of the intestinal barrier. Paneth cells produce AMPs, 
lysozyme, secretory phospholipase A2, C-lectin RegIIIγ, α- and 
β-defensins, and angiogenin-4 to protect the host from pathogenic 
bacteria while shaping the composition of the microbiota (33, 34). 
Paneth cells and their AMPs, particularly α-defensins, have been 
implicated in diseases of the intestine through the use of several 
animal models (33). One noteworthy study utilized two genetic 
mouse models to study the role of α-defensins, including DEFA5-
expressing transgenic mice and also mice that are deficient in 
FiGURe 1 | The neonatal intestinal immune system and its interaction in the pathogenesis of necrotizing enterocolitis (NeC). (A) The intestinal mucosal 
immune system is comprised of the cells of the epithelium, immune cells, and commensal bacteria. The epithelium consists of villi and crypts. Enterocytes, goblet 
cells, enteroendocrine cells, and tuft cells exist within the villi, whereas Paneth cells and stem cells occupy the base of the crypts. Immune cells consist of 
intraepithelial lymphocytes, T regulatory cells (Tregs), T cells, B cells, macrophages, and dendritic cells, which reside predominantly in the lamina propria underlying 
the epithelium. Commensal bacteria inhabit the lumen of the gut, which constantly interact with the epithelium and immune cells to help maintain protection against 
pathogenic bacteria. (B) In NEC, lipopolysaccharide from Gram-negative bacteria interact with toll-like receptor 4 (TLR4) expressed by predominantly by 
enterocytes, which results in the breakdown of the gut barrier, allowing for pathogenic bacterial translocation. A pro-inflammatory response follows resulting in 
increased production of pro-inflammatory cytokines (IL-6, IL-8, and TNF) as well as increased Th17 cells and decreased Tregs. The combination of these cellular 
responses with TLR4 signaling results in a profound inflammatory response and subsequently NEC.
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matrix metalloproteinase 7 (MMP7), which is required to activate 
α-defensins (35). Using 16S rRNA sequencing, they found there 
was an α-defensin-dependent change in the composition of the 
microbiota, such that there was a correlation between α-defensin 
deficiency, decreased populations of bacteria from the phylum 
Bacteroidetes, and increased populations of bacteria from the 
phylum Firmicutes (35). Moreover, in DEFA5 transgenic mice, 
there was a loss of segmented filamentous bacteria and interleu-
kin 17 (IL-17)-producing lamina propria T cells, substantiating 
the role of α-defensins and thus, Paneth cells in influencing the 
microbiota of the gut and modulating the intestinal immunologic 
response to pathogens (35).
The role of Paneth cells in disease has been well characterized 
in the studies on inflammatory bowel disease (IBD), specifically 
ileal Crohn’s disease (36). There are several susceptibility genes 
associated with Crohn’s disease, such as nucleotide-binding 
oligomerization domain-containing protein 2 (NOD2), which is 
expressed predominantly by Paneth cells in the small intestine 
(37–39). One such study evaluated known NOD2 loss-of-function 
gene mutations known to be risk factors for IBD in a group of 
very low birth weight infants (40). They found that the presence 
of two or more NOD2 genetic risk factors was an independently 
associated with the development of NEC and focal intestinal 
perforation (40). Moreover, NOD2-deficient mice develop ileal 
granulomatous inflammation in response to inoculation with 
Helicobacter hepaticus characterized by increased inflammatory 
cytokines and expression of Th1-related genes (41). This was 
restored with transgenic expression of α-defensin in Paneth 
cells (41). Moreover, in ileal Crohn’s disease, there is decreased 
expression of α-defensins, suggesting a relationship between the 
secretion of α-defensins by Paneth cells and the pathogenesis of 
Crohn’s disease. The involvement of Paneth cells in mediating 
protection against NEC is not well defined. However, animal 
models utilizing a Paneth-cell depletion method in the presence 
of Klebsiella pneumoniae have been shown to produce NEC-like 
intestinal injury, suggesting Paneth cells may have a role in NEC 
pathogenesis (42–44).
enteroendocrine Cells
Enteroendocrine cells encompass several cell types that are 
located throughout the gastrointestinal system and primarily act 
to secrete hormones in response to food stimuli (45). The role 
of enteroendocrine cells in the promotion of mucosal immunity 
is incompletely understood; however, there is interplay between 
the immune system and enteroendocrine cells (46). For example, 
enteroendocrine cells express TLRs, and accordingly, can release 
chemokines and defensins in response to bacterial antigens, sug-
gesting these cells have a role in the maintenance of intestinal 
homeostasis with respect to bacterial colonization (47, 48). 
Interaction with the gut microbiota is not limited to the expres-
sion of TLRs by enteroendocrine cells. Rather, there are several 
mechanisms by which these cells cooperate with the microbiota 
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(49). For example, L cells are a subset of enteroendocrine cells that 
secrete glucagon-like peptides 1 and 2 (GLP-1 and GLP-2) (45). 
Short-chain fatty acids (SCFAs) derived from gut microbiota can 
activate specific receptors of L cells, thereby influencing energy 
metabolism and gut barrier function via secretion of GLP-1 and 
GLP-2 (49). Accordingly, enteroendocrine cells have a unique 
interaction with the gut microbiota.
Furthermore, enteroendocrine cells have also been implicated 
in IBD. Friedrich et  al. (50) found that patients have elevated 
serum and colonic pro-inflammatory IL-17c and discovered that 
enteroendocrine and to a lesser extent goblet cells were the main 
producers of IL-17c. This demonstrates a relationship between 
the neuroendocrine system of the gut and the Th17 pathway of 
the immune system (50). Nonetheless, more studies are necessary 
to understand the role of enteroendocrine cells during intestinal 
inflammation and more specifically NEC.
Tuft Cells
Finally, there is a unique cell type of the intestinal epithelium called 
tuft cells, which are thought to be taste-chemosensory cells found 
in both the respiratory tract and gastrointestinal tract (51, 52). 
Tuft cells were initially identified by electron microscopy due to 
their unique morphology with their tubulovesicular system and a 
tuft of long, blunt microvilli (51, 52). There is increasing evidence 
for tuft cell involvement in immunity (53). More specifically, 
there is a newly discovered role of tuft cells in parasitic infections, 
whereby, they generate type 2 helper T cell responses to promote 
immunity against such infections (54–56). This is accomplished 
by the ability to secrete IL-25 in a transient receptor potential 
cation channel subfamily M member 5 (Trpm5)-dependent 
mechanism (51, 54–56). IL-25 promotes the expansion of type 2 
innate lymphoid cells, an important source of IL-13 (56). This is 
crucial because IL-13 acts to promote differentiation of both tuft 
and goblet cells contributing to the “weep and sweep” response 
of the intestine to parasitic helminth infections, which consists of 
goblet cell hyperplasia and increased smooth muscle contractility 
(56). Although there is currently no known role of tuft cells in 
the pathogenesis of NEC, these studies provide evidence that 
these cells are actively involved in the mucosal immunity of the 
intestine in addition to their chemosensory roles.
immune Cells
Immune cells that compose the innate and adaptive immunity 
of the intestine exist in the epithelium and lamina propria (57). 
The epithelium houses intraepithelial lymphocytes (IELs) and the 
cytoplasmic extensions of DCs that interdigitate between epithe-
lial cells (23, 57). Several cell types inhabit the lamina propria, 
including but not limited to DCs, macrophages, neutrophils, 
immunocompetent T and B cells, and T regulatory cells (Tregs) 
in addition to mesenchymal cell types, such as endothelial cells 
(23, 57). We will now discuss the various immune cells implicated 
in NEC, including T cells, Tregs, Th17 cells, IELs, B cells, mac-
rophages, and DCs.
T Cells
There is increasing evidence that immune cells have a primary 
role in the development of NEC, including but not limited to 
T cells. In one study, NEC was induced in recombination acti-
vating gene 1-deficient (Rag1–/–) mice, which lack functional T 
and B cells (58, 59). Compared to wild-type counterparts, these 
animals exhibited significantly decreased intestinal injury and 
mucosal cytokine production, suggesting they are protected 
from NEC development (59). Demonstrating that these cells 
have a causative role in NEC pathogenesis, susceptibility to NEC 
was restored with the adoptive transfer of naïve CD4+ T cells 
(59). Furthermore, recruitment and differentiation of T cells 
were found to be mediated by activation of TLR4 via cognate 
chemokine ligand 25 (59). Thus, this study demonstrates the 
principal role of immune cells in NEC, specifically CD4+ T cells, 
and their relationship to TLR4 signaling.
Relationship between Tregs  
and Th17 Cells
The roles of immune cells in NEC are dynamic, and there is 
an imbalance of immune cells that favor a exaggerated pro-
inflammatory state. This is remarkably demonstrated by the 
relationship between Tregs and Th17 cells. Forkhead box P3 
(Foxp3)-expressing Treg cells are essential for the maintenance 
of a stable equilibrium in the gut (57, 60). Tregs are important in 
counterbalancing inflammation and promoting antigen-specific 
IgA responses so as to maintain commensalism with gut micro-
biota (57, 61). In humans, intestinal Tregs are present as early 
as 23  weeks of gestation, suggesting an early role in intestinal 
homeostasis (60). In the intestinal lamina propria of both mice 
and premature infants with NEC, there is decreased production 
of Tregs and increased production of CD4+ Th17 cells mediated 
by STAT3 (59). Additionally, expression of the IL-17 receptor, 
IL-17RA is significantly increased in a TLR4-mediated manner 
(59). Importantly, IL-17 release by CD4+ Th17 cells results in 
intestinal mucosal injury, as demonstrated by impaired enterocyte 
tight junctions, increased enterocyte apoptosis, and decreased 
enterocyte proliferation, all of which are hallmark features of 
NEC (59). Similarly, in a study analyzing the T cell populations in 
human NEC, there was decreased Foxp3+ Tregs relative to effector 
T cells compared to controls, which correlated with a mucosal 
cytokine expression profile indicative of inhibited Treg expres-
sion (62). With NEC resolution, Treg cell populations recovered, 
suggesting either the inflammatory response observed in NEC 
decreases Treg populations acutely or inflammation is attenuated 
as Treg populations increase with mucosal healing (62).
The premature human gut is notable for increased expression of 
pro-inflammatory cytokines, specifically IL-6, which is involved 
in T cells differentiating toward a Th17 phenotype during NEC 
development (59). Importantly, in a mouse model of NEC, oral 
administration of all-trans retinoic acid (ATRA), which binds 
to the nuclear retinoic acid receptor to stabilize transcription of 
Foxp3 and repress transcription of RAR-related orphan receptor 
γt, resulted in decreased NEC severity, increased Tregs, decreased 
CD4+ Th17 cells, and attenuation of IL-17 expression (59). This 
suggests that the Tregs serve to provide a protective role in intes-
tinal homeostasis, which is disrupted in NEC.
Further studies demonstrated that Th17 recruitment and Treg 
depletion resulted in apoptosis of Lgr5+ intestinal stem cells within 
the crypts of Lieberkühn in an experimental model of NEC (63). 
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After exposure to recombinant IL-17, enteroids derived from 
intestinal stem cells exhibited decreased proliferation, decreased 
differentiation, and increased apoptosis (63). In addition, deple-
tion of Tregs led to increased intestinal crypt apoptosis, exacer-
bating the experimental murine NEC model (63). Importantly, 
these effects were reversed upon administration of ATRA with 
its ability to modulate lymphocyte populations toward a protec-
tive Treg phenotype (63). This highlights the potential use of 
retinoic acid as a therapeutic in the treatment and prevention of 
NEC. Taken together, NEC is an immune cell-mediated disease 
defined by an imbalance of lymphocytes shifted toward a Th17 
cell phenotype with a decrease in Tregs, which is destructive in 
this specific setting.
intraepithelial Lymphocytes
Intraepithelial lymphocytes are a group of heterogeneous 
lymphocytes of the innate immune system in the distinctive 
position to interact dynamically with the local gut environment 
and the mucosal adaptive immune system to maintain intestinal 
homeostasis (64). This unique population of IELs bears the T cell 
receptor γδ (65). They differ from TCRαβ T-cells in that they do 
not require antigen processing for effector function (65). They 
are important in the discussion of the infant gut due to their 
early development in embryogenesis (66, 67). IELs are involved 
in a multifaceted approach in the maintenance and repair of the 
epithelium through tight junction preservation, recognition of 
stressors, and regulation of inflammation (65). They are also 
involved in a dynamic cross talk with commensal bacteria, as 
commensal bacteria direct expression of key immunomodulatory 
and antibacterial responses by influencing gene transcription of 
IELs, while IELs prevent opportunistic commensal bacteria over-
growth in the setting of mucosal injury (68). Weitkamp et al. (66) 
determined that γδ IELs are the predominant IEL subtype in the 
immature intestine of mice and premature infants. Furthermore, 
they showed that in the intestine of infants with NEC, there 
was a reduction in the γδ IEL subset as compared to non-NEC 
controls (66). This study highlights the important role of γδ IELs 
in intestinal barrier protection and suggests a potential cellular 
target for NEC prevention.
B Cells and immunoglobulins
B cells are both important antigen-presenting cells (APCs) and 
integral members of adaptive immunity with their ability to 
secrete immunoglobulins as plasma cells, most notably IgA in 
the context of neonatal immunity. IgA can neutralize pathogenic 
bacteria to maintain intestinal homeostasis (9). The maternal IgA 
from colostrum and milk is an important source of immunity 
in the neonatal period. Secretory IgA (sIgA) is detected weeks 
after birth and increases progressively; however, preterm infants 
have decreased concentrations of sIgA compared to full-term 
infants (69, 70). One study found higher levels of sIgA from the 
colostrum and milk of mothers of preterm infants, suggesting 
immunological adaptation occurs in the setting of prematurity to 
enhance immunity with IgA and reinforces the benefits of breast-
feeding in this context (71). There are both early and long-term 
benefits of early exposure to maternal sIgA (72). In one study, 
they found weanling mice exposed to sIgA-deficient breast milk 
displayed increased colonization of draining lymph nodes with 
bacteria, specifically aerobic bacteria and the opportunist patho-
gen Ochrobactrum anthropi (72). At both weaning and adulthood, 
there were significant differences in the gut microbiota and the 
pattern of epithelial gene expression of the intestine, including 
genes associated with IBD, between these mice compared to mice 
exposed to sIgA (72). Accordingly, exposure to sIgA in breast 
milk promotes intestinal homeostasis in the neonatal period with 
long-term implications (72). Taken together, IgA is important in 
intestinal immunity, and maternal IgA is crucial given the imma-
turity of the immune system during the neonatal period.
Macrophages
Macrophages are important phagocytic and bactericidal cells of 
the immune system. Macrophages are activated after exposure 
to lipopolysaccharide (LPS) and interferon-γ, which then release 
pro-inflammatory cytokines and nitric oxide (57). To counteract 
excessive inflammation, intestinal macrophages are inhibited by 
tumor growth factor-β (TGF-β) (57) and have been implicated 
in NEC pathogenesis (73). Intestinal macrophages from healthy 
term infants have increased phagocytic and bactericidal activity 
as well as minimal inflammatory cytokine production when 
exposed to bacterial products, which is attributed to the anti-
inflammatory effects of transforming growth factor β2 (TGF-β2) 
(73). In contrast, the phenotype of macrophages during NEC is 
strongly inflammatory as demonstrated by increased expression 
of the gene, mothers against decapentaplegic homolog 7 (Smad7), 
an inhibitor of TGF-β2 (74, 75). Consequently, this interrupts 
TGF-β-mediated downregulation of the pro-inflammatory 
response by macrophages in NEC and thereby sensitizes mac-
rophages to bacterial products, leading to a significant pro-
inflammatory response (74). Taken together, the imbalance of 
macrophage effector responses toward an inflammatory state 
increases mucosal injury in NEC.
Dendritic Cells
Dendritic cells are specialized APCs that have the delicate role of 
mediating protective adaptive immunity in response to pathogens 
while maintaining intestinal homeostasis and commensal bacte-
ria (76). Although they are important in intestinal immunity, the 
role of DCs in NEC has not been fully elucidated. However, in 
one study using Cronobacter sakazakii to induce NEC in newborn 
mice, DCs were recruited from the lamina propria, resulting in 
intestinal barrier dysfunction via tight junction disruption and 
increased enterocyte apoptosis via TGF-β production (77). 
The study concluded that the presence C. sakazakii was able to 
modulate the activity of DCs to increase TGF-β production, 
which subsequently resulted in damage to the mucosal barrier 
integrity (77). This highlights the sensitive interaction between 
DCs and bacteria, which can be detrimental in the setting of 
NEC; however, more studies are necessary to further understand 
the role of DCs in NEC pathogenesis.
Neutrophils
Neutrophils are important effector cells of the innate immune sys-
tem distinguished by their ability to respond rapidly and robustly 
to tissue trauma, including the intestine. The role of neutrophils 
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in NEC pathogenesis has not been fully elucidated, but there are 
several studies to note. Small for gestational age (SGA) neonates 
are more likely to have neutropenia during the first few days after 
birth, and these infants with neutropenia were at increased risk for 
developing NEC compared to SGA infants without neutropenia 
(78). Moreover, in a model of C. sakazakii-induced experimental 
NEC, depletion of neutrophils and macrophages in the lamina 
propria resulted in increased production of pro-inflammatory 
cytokines and increased enterocyte apoptosis, thereby exac-
erbating the disease (79). This suggests both macrophages and 
neutrophils are important in early infection and their absence 
intensifies the inflammatory response observed in NEC. One 
study utilizing TNBS-induced enterocolitis to model NEC found 
the leukocyte infiltrate relatively devoid of neutrophils in the 
intestinal tissue (80). Taken together, impairment of neutrophil 
function is one component of NEC; however, more studies are 
necessary to determine whether this is a primary observation in 
NEC or secondary to the disease.
Peyer’s Patches
Peyer’s patches are unique structures found primarily in the distal 
intestine that serve as secondary lymphoid tissue. Compared to 
other secondary lymphoid tissues, Peyer’s patches are distinguished 
by their significant exposure to a diverse group of antigens, from 
the gut microbiota to food antigens (81). Antigens are delivered 
by M cells of the epithelium, and upon activation, generate B cells 
and plasma cells to maintain mucosal immunity (81). Peyer’s 
patches appear in the intestine at 11 weeks, but continue to develop 
throughout gestation (82). Moreover, their numbers increase in 
proportion to gestational maturation, and thus, premature infants 
have less Peyer’s patch numbers and decreased maturation (82). It 
is unknown if this has clinical significance in the setting of NEC. 
Accordingly, more studies are necessary to determine if Peyer’s 
patches have a role in NEC as a consequence of prematurity.
CeLL SiGNALiNG
The innate immune system of the intestine is intricately involved 
in the pathogenesis of NEC. An important aspect of the innate 
immune system is the expression of PRRs, including TLRs and 
NOD proteins, that can interact with the local gut environment 
and initiate several signaling pathways. We will review these 
essential components and their cellular responses with specific 
attention to aberrant TLR4 signaling, which is well studied in the 
pathogenesis of NEC.
PRRs: TLR and NOD
Pattern-recognition receptors are expressed throughout the cells 
of the body as a means of detecting threats to local homeostasis. 
The cells of the intestinal epithelium and immune cells express 
TLRs and NOD proteins, which can detect pathogen-associated 
molecular patterns such as the LPS of Gram-negative bacteria 
and flagella and consequently initiate an appropriate response to 
these bacterial stressors (23).
Specifically, in the case of TLR4 activation, signaling results 
in nuclear factor-κB (NF-κB) activation, subsequent cytokine 
production, resulting in an acute inflammatory response (23). 
TLRs are expressed by intestinal epithelial cells and immune 
cells of the lamina propria and are involved in epithelial cell 
proliferation, IgA production, maintenance of tight junctions, 
and AMP expression (23, 57, 83). TLR4 is of specific interest in 
the understanding of NEC pathogenesis, as its overexpression in 
the setting of prematurity yields a significant pro-inflammatory 
response and dysfunction of the epithelium (84). TLR4 is 
expressed by intestinal epithelial cells (85), which we will discuss 
in greater detail with respect to epithelial TLR4 expression and 
the development of NEC.
However, other TLRs have also been implicated in NEC 
pathogenesis. For example, TLR2 is expressed throughout the 
intestinal epithelium, including enterocytes, as well as various 
immune cells found in the lamina propria. Gram-positive bacte-
ria in the intestine can engage TLR2, which can induce MyD88, 
which is a major adaptor for TLR2/TLR4, with subsequent NF-κB 
activation (86). TLR2 through the regulation of tight junctions is 
able to maintain gut barrier integrity, and thus, its deficiency can 
predispose the intestine to stress-induced injury (86). The role of 
TLR2 in NEC has not been fully elucidated thus far. However, in 
a rat model of NEC, investigators have found upregulation of ileal 
TLR4 and TLR2 in several studies, which precedes histological 
evidence of mucosal injury, suggesting a causative role in NEC 
pathogenesis (87, 88). Moreover, certain therapeutic interven-
tions that reduced NEC severity in animal models downregulated 
the expression of TLR2 and TLR4, including glutamine (88) and 
probiotic Bifidobacterium (89). Thus, aberrancy in TLR4 signal-
ing is not solely responsible for the pro-inflammatory response 
observed in NEC.
Moreover, NOD1 is also expressed by intestinal epithelial cells, 
which in response to the Gram-negative bacterial peptidoglycan, 
elicits an immune response to induce the formation of gut-
associated lymphoid tissue, specifically Peyer’s patches (9, 57). 
Conversely, NOD2 is expressed highly by monocytes and Paneth 
cells at baseline, and by enterocytes when under stress (9, 57). 
NOD2 is important in the cross talk between T-cells and intesti-
nal epithelium to downregulate inflammation by inhibiting TLR 
signaling (9, 57). One study demonstrated that NOD2 activation 
inhibited TLR4 in enterocytes, thereby decreasing enterocyte 
apoptosis and attenuating the severity of experimental NEC (90). 
In this study, NOD2 provided protection from TLR4-mediated 
enterocyte apoptosis via a novel SMAC-diablo pathway (90). This 
suggests that modulation of this cross talk may provide a potential 
means of decreasing NEC severity (83, 90). Furthermore, NOD2 
is important in regulating commensal bacteria such that NOD2-
deficient mice had decreased ability to prevent colonization by 
pathogenic bacteria in the intestine (91). Conversely, germ-free 
mice had significantly decreased NOD2 expression, but this 
expression was inducible with the introduction of commensal 
bacteria, demonstrating the feedback mechanism by which 
NOD2 regulates the gut microbiota (91). Upon ligand binding, 
both NOD1 and NOD2 activate NF-κB, and independently func-
tion by activating this signaling pathway, but can also modulate 
TLR4 signaling in this way (92). Thus, TLR and NOD signaling 
exemplify the delicate interaction between luminal bacteria and 
the innate immune system of the gut and how perturbations in 
these pathways may lead to NEC development.
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TLR4 Signaling
One of the major cornerstones in understanding the development 
of NEC is the role that TLR4 signaling plays in the pathogenesis 
(59, 85, 93–100). Activation of TLR4 within the intestinal epithe-
lium in the setting of prematurity results in decreased enterocyte 
proliferation, increased enterocyte apoptosis, disruption of 
intestinal barrier integrity, and bacterial translocation, resulting 
in a systemic inflammatory response (26, 84, 95, 97). As a result 
of bacterial translocation, TLR4 is activated on the endothelium 
of premature gut, leading to impaired blood flow and subsequent 
intestinal ischemia via reduction of endothelial nitric oxide 
synthase (eNOS) (100, 101). The differential response to stress 
between premature and full term neonates rests in the increased 
expression of TLR4 in prematurity (96). TLR4 is expressed at 
high levels in the developing intestine as it is involved in normal 
gut development in both mice and humans (8). In the setting of 
prematurity, TLR4 expression remains elevated, resulting in a 
hyper-active, exaggerated response to stressors upon coloniza-
tion by bacteria (8).
Furthermore, TLR4 is necessary for the development of NEC, 
and its enhanced expression is not a consequence of the disease. 
In studies utilizing TLR4-mutant mice strains (C3H/HeJ mice), 
lack of functional TLR4 was protective against the development 
of NEC, such that wild-type mice had increased NEC severity, 
increased enterocyte apoptosis, reduced enterocyte proliferation, 
and impaired restitution compared to TLR4-mutant mice (97). 
These results were further supported utilizing mice with either 
global TLR4 deletion or intestinal-specific TLR4 deletion (26). 
Both groups of mice were protected from the development of 
experimental NEC with preservation of mucosal integrity and 
minimal elevation of pro-inflammatory cytokines (26). These 
studies highlight the causative role of aberrant TLR4 signaling 
expressed by IECs in NEC pathogenesis.
Aberrant TLR4 signaling also has a direct role in the break-
down of the gut barrier in NEC. In healthy mucosa, healing of the 
epithelium occurs in two phases, intestinal restitution followed 
by enterocyte proliferation, whereby healthy IECs migrate to 
injured mucosa followed by increased generation of IECs from 
stem cells of the intestinal crypts (18). TLR4 signaling impairs 
IEC migration, thus impairing restitution (102, 103). Moreover, 
enterocyte proliferation is significantly decreased in NEC, dimin-
ishing the ability to heal in the setting of mucosal injury (18, 95, 
97–99). Importantly, autophagy is a response to cellular stress and 
has been found to be upregulated in NEC (104). Furthermore, 
TLR4 signaling induces autophagy of enterocytes in both mouse 
and human studies (105). An experiment utilizing intestinal 
epithelial-specific autophagy gene ATG7 conditional knockout 
mice demonstrated autophagy via ATG7 was required for NEC 
development as these mice were protected from NEC (105). 
TLR4-induced autophagy leads to impaired enterocyte migration, 
demonstrating the effects of TLR4 signaling on the epithelium are 
multifaceted and interconnected (105). Ultimately, the deficiency 
in mucosal repair via enterocyte restitution and proliferation in 
the setting of NEC weakens the integrity of gut, allowing for bac-
terial translocation and the downstream inflammatory response 
observed in this disease.
Genetic Risk Factors
The study of genetic risk factors in NEC is an important com-
ponent in understanding the signaling pathways that involve 
the innate immune system. There are several genetic association 
studies evaluating the relationship between specific genetic risk 
factors and the development of NEC (106). Genetic variation 
that affects TLR signaling increases the predisposition of the pre-
mature intestine to inflammatory aberrancy. The gene SIGIRR is 
important in the inhibition of LPS-induced inflammation (107). 
Loss-of-function mutations of SIGIRR result in unregulated TLR 
signaling, thereby predisposing infants to NEC (107). One study 
specifically evaluated the roles of single nucleotide polymorphisms 
of important genes in TLR signaling. They found in studying the 
blood samples of very low birth weight infants a relationship 
between NFKB1 and NFKBIA variants and the development of 
NEC, such that NFKB1 increased susceptibility to NEC, whereas 
NFKBIA decreased susceptibility to NEC (108). However, there 
was no association between TLR2, TLR4, TLR5, TLR9, IRAK1, 
and TIRAP genes and the development of NEC in this patient 
population (108). Genetic risk factors for NEC have not just been 
limited to TLR and NOD signaling pathways. For example, one 
study evaluating the autophagy gene ATG16L1 in premature 
infants found that hypomorphic variants conferred protection for 
the development of NEC (109). This study highlights the breadth 
of possible genetic risk factors in the NEC. Taken together, genetic 
predisposition to NEC is valid, and further large scale studies will 
likely reveal more genetic relationships and disease development.
GUT MiCROBiOTA
The intricate relationship between gut microbiota and mucosal 
immunity is central to the discussion of NEC pathogenesis. The 
gut is exposed to a multitude of microbes, and it is the role of 
the intestinal immune system to distinguish commensal bacteria 
from pathogenic bacteria, particularly as the gut flora develops 
early in life. There are several variables that influence the micro-
bial composition of the intestine; however, new evidence suggests 
that disruption of normal bacterial flora is involved in NEC 
pathogenesis. We will now explore the role of gut microbiota in 
the setting of prematurity.
Factors influencing Gut Microbiota
There is a significant interest in understanding the composition 
of the gut microbiota and its relationship to the pathogenesis of 
NEC. Several factors influence the neonatal microbiota, including 
gestational age, mode of delivery (vaginal vs. cesarean section), 
antibiotic treatment, and diet (breast milk vs. formula feedings) 
(110). Colonization occurs in two waves, and the first wave is 
dependent on the mode of delivery (111). For example, one study 
found that compared to infants born vaginally, infants born via 
cesarean section had decreased populations of Bifidobacteria 
and Bacteroides, while there was an increased population of 
Clostridium difficile (112). The second wave is dependent on 
feeding method, which often differs between premature and 
term infants, as breast milk and formula feedings have different 
bacterial compositions and access to breast milk can be limited in 
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prematurity with delayed initiation of enteral feeding in preterm 
newborns (113). More specifically, formula-fed infants have 
increased populations of Enterobacteriaceae, Bacteroides species, 
and C. difficile in the stool compared to infants fed breast milk 
(112, 114).
Moreover, duration of antibiotic exposure is associated with 
the development of NEC (115, 116). In one retrospective study 
investigating the association between antibiotic exposure and 
subsequent diagnosis of NEC in infants, they found that antibiotic 
exposure duration is associated with increased risk of developing 
NEC (115). When sepsis was eliminated as a potential confounder, 
the probability of developing NEC was increased 20% per day of 
antibiotic exposure (115). Strikingly, antibiotic exposure greater 
than 10 days in neonates resulted in an approximately threefold 
increased risk of developing NEC (115). Another retrospective 
study aiming to assess the association between initial antibiotic 
therapy in extremely low birth weight infants and NEC, found 
there was an increased risk of developing NEC after initial 
empiric antibiotic treatment in the first three postnatal days (116). 
Empiric antibiotic treatment for greater than 5 days, which the 
study defined as prolonged antibiotic treatment, was associated 
with the development of NEC and death in extremely low birth 
weight infants in the setting of sterile blood cultures (116). These 
studies highlight the need to be judicious in the implementation 
of empiric antibiotic treatment in preterm infants.
A recent study utilizing 16S rRNA gene pyrosequencing sug-
gests the most important variable influencing the composition of 
premature gut microbiota is the degree of prematurity (117). Using 
922 specimens from 58 subjects, they found an ordered, tightly 
controlled microbial progression of bacterial classes: Bacilli to 
Gammaproteobacteria to Clostridia (117). Other factors, includ-
ing antibiotics, mode of delivery, and age influenced the pace of 
the progression of bacterial classes, but the particular sequence 
of development remained the same (117). This is important as 
more studies demonstrate the significance of dysbiosis and the 
development of NEC (113, 118–122).
Dysbiosis in NeC
The differences in microbial colonization between preterm 
infants and term infants suggests the possible role of dysbiosis on 
the pathogenesis of NEC. The onset of NEC occurs 2–6 weeks of 
life with the highest risk of NEC occurring at a corrected age of 
29–33 weeks (123), only after microbial colonization of the gut 
(2, 124, 125), highlighting the role of gut microbiota in disease 
pathogenesis. To date, no specific microbial pathogen has been 
identified to be responsible for the development of NEC (119, 
124, 125). However, resected intestinal tissue with active NEC 
demonstrated increased microbial burden and an abundance of 
strict anaerobes with a decrease in community diversity (126). 
Moreover, until recently, it was unclear if abnormal gut micro-
biota is a cause or consequence of NEC (127). A prospective 
case–control study by Warner et al. (127) helps to define the role 
that the microbiota plays in NEC development. In 166 very low 
birth weight infants, 3,586 stool samples were prospectively col-
lected, and of these subjects, 46 developed NEC (127). Differences 
between the NEC cases and matched controls emerged after 
1  month with a predominance of Gammaproteobacteria and 
decreased quantities of Negativicutes and Clostridia in infants that 
went on to develop NEC, with the strongest correlation between 
bacteria composition and development of NEC occurring prior 
to 27 weeks gestation (127). This study suggests an increased con-
centration of Gram-negative facultative bacteria is detrimental, 
possibly due to their ability to activate TLR4 via LPS (84, 122). 
Conversely, infants with NEC had significantly decreased obligate 
anaerobes (127), which interestingly produce anti-inflammatory 
SCFAs (128). These results suggest that interventions focused on 
modulation of the gut bacteria may play a role in preventing NEC.
PROTeCTive STRATeGieS AGAiNST NeC
With advancements in our knowledge of NEC, there are several 
potential preventative and therapeutic strategies that did not exist 
decades ago. We will review several of these strategies with respect 
to how they influence the intestinal immune system (Figure 2). 
These advancements target several aspects of the intestinal 
immune system, such as TLR4 signaling modulation, gut barrier 
integrity, immune cell composition, and the gut microbiota, all 
of which have been described with their individual roles in NEC. 
There have been several studies that demonstrate the importance 
of providing breast milk to premature infants instead of formula. 
Human breast milk contains several bioactive components 
beneficial to the neonate some of which include: epidermal 
growth factor (EGF), heparin-binding EGF-like growth factor, 
platelet-activating factor (PAF) acetylhydrolase, human milk 
oligosaccharides (HMOs), nitrates/nitrites, l-arginine, lactofer-
rin, and probiotics (8, 129, 130). We will review several breast 
milk components and the evidence supporting the mechanisms 
by which they impact the intestinal mucosal immunity during 
NEC. We will also discuss the use of antenatal corticosteroids and 
delayed umbilical cord clamping in the prevention of NEC.
Breast Milk
Breast milk has a well-established role in the prevention of NEC 
and clinically represents one of the most effective strategies in 
decreasing the incidence and progression of NEC (130). New pre-
clinical evidence has demonstrated that breast milk is capable of 
attenuating the TLR4-mediated pro-inflammatory response inte-
gral to NEC pathogenesis by activating the receptor for epidermal 
growth factor (EGFR), revealing the interplay between the EGF 
pathway and the hallmark TLR4 signaling of NEC (95). These 
inhibitory effects on TLR4 signaling were mediated by breast 
milk preventing the activity of the downstream target glycogen 
synthase kinase 3β, resulting in enhanced mucosal healing, intes-
tinal stem cell proliferation and decreased enterocyte apoptosis 
(95). In seeking to determine the particular component in breast 
milk that mediated the protective effects, when EGF was either 
removed or its receptor, EGFR was inhibited, the protection on 
experimental NEC and TLR4 signaling was abolished (95). Taken 
together, these mechanistic studies describe one of the ways breast 
milk protects the intestinal epithelium against NEC.
epidermal Growth Factor
Several other studies have looked at the protective role of EGF itself 
against NEC. In a neonatal rat model of NEC, administration of 
FiGURe 2 | Mechanisms of protective strategies in necrotizing enterocolitis (NeC). (A) The enterocyte is the predominant cell type of the epithelium and 
significantly contributes to the exaggerated pro-inflammatory response observed in NEC upon activation of toll-like receptor 4 (TLR4) by Gram-negative bacteria 
lipopolysaccharide (LPS). TLR4-mediated activation of nuclear factor-κB (NF-κB) results in increased expression of pro-inflammatory cytokines, such as IL-1, IL-6, 
and TNF-α. However, this signaling pathway can be attenuated through various mechanisms. Epidermal growth factor (EGF), which is found in breast milk and 
amniotic fluid, inhibits this pathway via inhibition of glycogen synthase kinase-3 beta (GSK3β). The human milk oligosaccharide 2′-fucosyllactose (2′FL) also 
attenuates the TLR4 pro-inflammatory signaling pathway. Finally, intracellular pattern recognition receptor nucleotide-binding oligomerization domain-containing 
protein 2 upon stimulation by pathogen associated molecular patterns via second mitochondria-derived activator of caspase/direct inhibitor of apoptosis-binding 
protein with low pI (SMAC-diablo). (B) Endothelial cells have an integral role in the pathogenesis of NEC. Endothelial cells express TLR4, and upon stimulation by 
LPS following gut barrier dysfunction, decrease the expression of endothelial nitric oxide synthase (eNOS), thereby reducing the formation of nitric oxide (NO), an 
important vasodilator. This results in intestinal ischemia and subsequent NEC. However, several protective strategies increase the production of NO, including 
heparin-binding EGF-like growth factor (HB-EGF) and 2′FL by increasing expression of eNOS. Nitrates (NO3− ) and nitrites (NO2− ) can be found in breast milk and are 
precursors to NO, thus increasing NO production. Finally, l-arginine is required for NOS-dependent formation of NO. Supplementation with HB-EGF, nitrates, nitrites, 
and l-arginine are protective in NEC with their ability to improve intestinal blood supply via NO-mediated vasodilation.
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EGF alone reduced both the incidence and severity of the disease 
(131). EGF administration resulted in significantly decreased 
epithelial permeability, normalized expression of tight junction 
proteins, increased goblet cells (28), and inhibited enterocyte 
apoptosis (132), all of which are protective hallmarks in NEC 
(26, 59, 95). Moreover, another mechanism by which EGF pro-
vides protection against NEC is inhibition of autophagy (133), 
a lysosomal pathway of self-digestion that has been shown to 
be activated in mice and infants with NEC (105). Additionally, 
a recent study demonstrates that a hypomorphic variant in an 
autophagy-related gene, ATG16L1 is associated with NEC in 
premature infants (108). This further underlies the importance 
of determining which infants are the most susceptible to NEC, so 
that protective strategies including EGF administration may be 
tailored to those individuals.
Amniotic Fluid
As discussed above, EGF administration mediates several protec-
tive effects on the intestine and is found in breast milk as well 
as amniotic fluid. We demonstrated that amniotic fluid inhibited 
TLR4-mediated inflammatory signaling in the fetal and neonatal 
intestinal epithelium in a manner dependent on EGFR (94). 
Intestinal EGFR expression was low in premature infants with 
NEC compared to that of a fetus or at the time of reanastamosis 
after NEC had resolved (94). The protective effects of amniotic 
fluid have been described in experimental NEC models in several 
species including neonatal mice (94), rats (134), and piglets (135). 
Other investigators have examined amniotic fluid outside the set-
ting of EGF in the study of NEC. In a neonatal rat model of NEC, 
administration of amniotic fluid stem cells attenuated NEC by 
increasing enterocyte proliferation and decreasing apoptosis in a 
cyclooxygenase 2 dependent mechanism (136). In other studies, 
the administration of amniotic fluid resulted in differences in 
gut microbiota and reduced intestinal permeability compared to 
controls (137). Taken together, the ingredients in both breast milk 
and amniotic fluid provide important protective mechanisms to 
counter-regulate the detrimental pro-inflammatory effects in the 
intestine afflicted by NEC.
Heparin-Binding eGF-Like Growth  
Factor (HB-eGF)
Heparin-binding EGF-like growth factor is found in breast milk 
and amniotic fluid and provide numerous protective effects in 
models of intestinal injury and NEC (138). In mice, overexpres-
sion of the HB-EGF gene is protective against the development of 
NEC (139), whereas deletion of HB-EGF increases susceptibility 
to experimental NEC (140). As described previously, an important 
component in the pathogenesis of NEC is the disruption of gut 
perfusion and decreased expression of the vasodilatory molecule 
eNOS (100). In neonatal mice subjected to experimental NEC, 
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impairment of intestinal microvascular blood flow was improved, 
and there was decreased epithelial injury with administration of 
HB-EGF (141). Moreover, HB-EGF promotes angiogenesis with 
upregulation of eNOS and subsequent production of nitric oxide 
via the PI3K pathway (142, 143).
Heparin-binding EGF-like growth factor is also unique 
in its ability to modulate the intestinal immune system. For 
example, there are subtypes of macrophages, which can either 
be pro-inflammatory (M1) or anti-inflammatory (M2) (144). 
Macrophage infiltration in NEC was marked by a predomi-
nance of M1 pro-inflammatory macrophages and treatment 
with HB-EGF resulted in increased M2 anti-inflammatory 
macrophages, thereby protecting against experimental NEC. 
Moreover, HB-EGF also helps in maintaining gut barrier integrity 
with increased enterocyte proliferation (145) and migration (146) 
as well as decreased apoptosis of enterocytes (147), which is a 
common theme among the potential protective strategies in NEC.
Platelet-Activating Factor Acetylhydrolase 
(PAF-AH)
Platelet-activating factor is a potent phospholipid inflammatory 
mediator involved in the pathogenesis of NEC in human and 
animal studies (148, 149). Activation results in epithelial cell 
damage, increased apoptosis, increased mucosal permeability, 
disruption of tight junctions, leukocyte and platelet aggrega-
tion, and vasoconstriction, disrupting mucosal integrity (148, 
149). Importantly, PAF-AH is capable of catabolizing PAF and 
decreases the destructive properties of PAF in the intestine (150). 
Additionally, breast milk contains PAF-AH, which is one com-
ponent in breast milk thought to provide protection against the 
development of NEC (150, 151). The clinical relevance of PAF is 
demonstrated by the findings that compared to controls, infants 
with NEC display increased plasma and stool PAF concentrations 
and decreased plasma PAF-AH, which is responsible for PAF 
breakdown (152–154). In neonatal mouse and rat models, NEC 
susceptibility decreased with inhibition of PAF and increased with 
PAF-AH depletion (155–157). Of note, PAF was found to induce 
TLR expression in the intestine, providing a connection between 
two pathways involved in NEC pathogenesis, thereby suggest-
ing luminal PAF in the preterm intestine may upregulate TLR 
expression and subsequently promote a pro-inflammatory state 
(158). Taken together, PAF-AH may serve as an important target 
by inhibiting intestinal inflammation and epithelial disruption.
Human Milk Oligosaccharides
Human milk oligosaccharides are carbohydrates recently heralded 
as protective components within breast milk. There are several 
means by which HMOs are protective in the setting of NEC. We 
recently demonstrated that 2′-fucosyllactose (2′FL) is an abun-
dant HMO that is protective against NEC in mice via modulation 
of the vasodilatory molecule, eNOS expression and subsequently 
enhancing intestinal perfusion (101), which has been previously 
shown to be impaired in NEC (100). Moreover, 2′FL is capable 
of attenuating inflammation, and we demonstrated that 2′FL 
decreased the expression of several pro-inflammatory markers 
including IL-6, IL-1β, inducible nitric oxide synthase, and TLR4 
(101). Importantly, HMOs have been shown to influence bacterial 
colonization in the intestine during the critical neonatal period in 
several studies (159–165). In another study, the HMO 2′FL inhib-
ited the release of IL-8 by IECs in the setting of bacterial infection 
by attenuating the expression of CD14 (166). However, this effect 
was not observed in IECs that were not exposed to the bacterial 
pathogen, showing that HMOs are capable of modulating specific 
inflammatory pathways during infection (166). Another HMO, 
disialyllacto-N-tetraose, was capable of reducing the NEC sever-
ity in neonatal rats (167). Taken together, these studies advance 
our understanding of the effects of HMOs in preventing against 
NEC and may provide a nutritional preventative strategy worth 
pursuing.
The breast milk composition of HMOs varies among moth-
ers, which in turn influences the microbiota of their offspring. 
Specifically, mothers with inactive alleles of the gene fucosyltrans-
ferase 2 (FUT2) are referred to as non-secretor mothers (168), and 
this mutation leads to changes of the microbiota of their infants. 
Specifically, infants in this setting had delayed establishment of 
the genus Bifidobacterium, which are early colonizers in breastfed 
infants (168). This suggests HMOs can enrich certain beneficial 
populations of bacteria. Moreover, since the individual composi-
tion of breast milk varies widely, attention to these details may 
provide a novel strategy of personalized breast milk fortification 
to prevent NEC in preterm infants.
Nitric Oxide
One of the hallmarks of NEC pathogenesis is the disruption of 
the microcirculatory perfusion to the gut, which is regulated by 
endothelial expression of TLR4 (100). Specifically, endothelial 
TLR4 signaling impairs intestinal perfusion and decreases eNOS 
expression and accordingly nitric oxide (NO), such that mice 
with selective endothelial TLR4 deletion exhibited preserved 
mucosal integrity and decreased intestinal ischemia (100). In this 
context, TLR4 signaling promotes bacterial translocation with 
the disruption of the epithelial barrier, intensified by impaired 
intestinal perfusion by decreased expression of eNOS with the 
activation of endothelial TLR4.
Human breast milk contains sodium nitrate, which is a pre-
cursor to nitrite and NO production, a key vasodilatory molecule 
involved in maintaining intestinal perfusion (100). Interestingly, 
the concentration of sodium nitrate is higher in breast milk as 
compared to formula (100), and when compared to adults, 
infants in the NICU receive significantly less dietary nitrites and 
nitrates (169). Bacterial conversion of nitrates to nitrites first 
occurs in saliva, which can then be converted to nitric oxide via 
both NOS-independent mechanisms in the stomach and NOS-
dependent mechanisms in the intestine from the amino acid 
l-arginine (170). This illustrates the interaction of bacteria and 
the gastrointestinal system and also highlights the importance 
of having dietary nitrates and nitrites in the form of breast milk 
during the critical neonatal period. This further suggests there 
is the opportunity to improve the deficits in dietary nitrites and 
nitrates inherent to neonates to prevent NEC. Moreover, studies 
have shown that enteral supplementation of l-arginine was not 
only safe but was able to reduce incidence and severity of NEC 
in very low birth weight preterm infants (171, 172). Accordingly, 
l-arginine, nitrates, and nitrites in the neonatal period are not 
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only important but given their ability to modulate the microcir-
culation of the preterm intestine, they have utility as a preventa-
tive strategy for NEC.
Lactoferrin
Lactoferrin is found in secretory fluids including breast milk and 
colostrum, where it acts an important member of mucosal immu-
nity with its antimicrobial properties (173), ability to modulate 
the gut microbiota (174), and maturation of the intestine by 
inducing enterocyte growth and proliferation (175). Accordingly, 
the use of lactoferrin supplementation in preterm infants to pre-
vent complications has been studied. The most recent Cochrane 
Review suggests that there is utility in the administration of oral 
lactoferrin prophylaxis due to the decrease in the development 
of NEC and late-onset sepsis without adverse effects (176–180). 
Another study evaluated the use of recombinant human lacto-
ferrin (talactoferrin or TLf) in infants with a birth weight of 
750–1,500 mg as means of reducing infection (181). There was 
no associated toxicity in the administration of TLf, and there was 
a trend toward less infectious morbidity in infants treated with 
TLf (181). Thus, lactoferrin administration in low birth weight 
infants is a promising preventative strategy against NEC with no 
adverse effects reported thus far.
Probiotics
Probiotics have generated significant interest in the prevention of 
NEC given the increasing data regarding the relationship between 
the gut microbiota and disease development. Prophylactic enteral 
probiotics show significant promise in the prevention of NEC. A 
Cochrane Review concluded probiotics in the setting of prema-
turity prevent severe NEC and decrease all-cause mortality (182). 
A more recent systematic review and meta-analysis utilizing 
additional studies supported these findings (183). As probiotics 
continue to be investigated, it is important to recognize there is 
significant heterogeneity with organisms chosen and dosing regi-
mens across the studies. Bifidobacterium lactis has been studied 
in isolation in clinical studies. In a prospective randomized case–
control study, administration of B. lactis-supplemented formula 
resulted in decreased intestinal permeability as measured by a 
sugar absorption test, suggesting B. lactis is important in main-
taining epithelial integrity (184). In another clinical study, B. lactis 
Bb12 supplementation influenced the gut microbiota such that 
supplementation increased the number of Bifidobacterium spp. 
and reduced the number of Enterobacteriaceae and Clostridium 
spp., which may be implicated in NEC pathogenesis, in stool 
samples of preterm infants (185). It is important to note that the 
largest clinical trial for a specific probiotic, Bifidobacterium breve 
BBG-001, found no benefit in the administration of this probiotic 
in preterm infants to prevent NEC (186). More clinical studies 
evaluating the utility of specific organisms within probiotic 
regimens are necessary.
Moreover, there are several mechanisms by which probiotics 
can prevent the development of NEC (187). Two studies high-
light our present knowledge of NEC pathogenesis as related to 
mucosal immunology. Bifidobacterium adolescentis is able to 
alter TLR4, TOLLIP, and SIGIRR expression in preterm neonatal 
rats, suggesting it is able to downregulate the TLR4-mediated 
pro-inflammatory response observed in NEC (188). Oral 
administration of Lactobacillus rhamnosus HN001 attenuated 
NEC severity in both premature piglets and newborn mice and 
the mechanism mediating this effect was via TLR9 activation 
(189). Lactobacillus reuteri in neonatal mice was able to increase 
enterocyte migration, enterocyte proliferation, and crypt height 
of the epithelium. This counters the impairment in enterocyte 
migration and proliferation that serve as hallmarks of NEC-
mediated gut barrier dysfunction (190). These studies suggest 
probiotics are able to interact with the mucosal immunity of 
the gastrointestinal tract, thereby offering a viable preventative 
strategy in clinical NEC management.
Antenatal Steroids
Corticosteroids are often administered in the antenatal period 
to reduce mortality and morbidities associated with prematurity. 
Based on a Cochrane Review, the use of a single course of antenatal 
corticosteroids is recommended for all women at risk for preterm 
birth (191). In addition to accelerating fetal lung maturation, 
antenatal corticosteroids are associated with decreased likeli-
hood for the development of necrotizing enterocolitis analyzing 
8 studies with 1,675 infants total (191). A more recent clinical 
study supports these findings, in which there were significant 
differences between infants that received full course antenatal 
steroids and infants that did not, such that prompt administra-
tion of a full course of antenatal corticosteroids decreased the 
incidence of NEC and mortality (192). Presently, it is unknown 
the mechanism by which corticosteroids are protective in NEC. 
However, with our knowledge of the primary role of immune cells 
in the pro-inflammatory response in NEC, corticosteroids serve 
as an interest of study with their ability to modulate the immune 
system.
Umbilical Cord Clamping
There is debate on the optimal interval of time between infant 
delivery and umbilical cord clamping in the setting of prematu-
rity. Delayed cord clamping provides more placental transfusion 
between the placenta and the newborn, whereas immediate cord 
clamping allows for immediate resuscitation of the premature 
newborn by a neonatologist (193). A Cochrane Review found 
that delayed cord clamping decreased the incidence of NEC (193); 
however, larger studies are necessary to evaluate this finding as 
well as the long-term effects of immediate vs. delayed cord clamp-
ing. In a more recent study, umbilical cord milking, which utilizes 
the same principle behind delayed umbilical cord milking also 
conferred protection against the development of NEC in preterm 
infants (194). The mechanisms by which umbilical cord clamping 
and umbilical cord milking provide protection against NEC are 
incompletely understood and warrant further investigation.
immunoglobulins
The roles of B cells and immunoglobulins in the setting of NEC are 
not fully understood in the context of disease development and 
preventative strategies. A trial of oral immunoglobulins admin-
istration has been tried for their presumed immunoprotective 
effects as prophylaxis in preterm infants (195). However, based 
on a recent Cochrane Review of three randomized trials, there 
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is no protective role against NEC with the oral administration of 
immunoglobulins in the neonatal period, specifically with IgG or 
a combination of IgG/IgA, as these studies did not demonstrate 
a significant reduction in NEC incidence (195–198). A trial of 
oral IgA alone powered for the prevention of NEC in low birth 
weight neonates would be beneficial given the known beneficial 
properties of sIgA in breast milk (195). Nonetheless, more studies 
are necessary to appreciate the role of IgA in NEC pathogenesis 
and as a viable prophylactic or treatment strategy.
CONCLUSiON
Necrotizing enterocolitis is a devastating disease of prematu-
rity and recent evidence demonstrates incredible promise for 
prevention with continuous advancements in the field. These 
advancements are not limited to mucosal immunology as 
recent attention to the interplay of intestinal immune system, 
which includes epithelial integrity, immune cell composition, 
TLR4 signaling, intestinal microbiota, has yielded expansion 
of our understanding of the disease and how to best prevent its 
development. One of the most important themes of this review 
is the dynamic interaction of the components that comprise the 
mucosal immunity of the intestine. Several aspects are integral to 
maintain intestinal homeostasis, and there is no one component 
singularly responsible for the development of NEC. Rather, it is 
an intricate balance of many variables, which yield numerous 
therapeutic potentials in treating and preventing this disease. The 
goal of this review was to highlight these recent innovations and 
mechanistic insights into how administration of various treat-
ments impacts the intestinal immune system and may alleviate 
NEC in premature infants.
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